Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | -1.38 Million USD | -116.65% |
| 2021 | 8.31 Million USD | 544.71% |
| 2020 | -1.87 Million USD | -1.36% |
| 2019 | -1.84 Million USD | -108.29% |
| 2018 | 22.25 Million USD | -14.26% |
| 2017 | 25.95 Million USD | 8839.06% |
| 2016 | -297 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 Q2 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q4 | -357 Thousand USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 FY | -1.38 Million USD | -116.65% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q4 | - USD | -100.0% |
| 2021 Q2 | 3 Million USD | 0.0% |
| 2021 Q3 | 6.75 Million USD | 125.0% |
| 2021 FY | 8.31 Million USD | 544.71% |
| 2020 FY | -1.87 Million USD | -1.36% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | -1.84 Million USD | -108.29% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | 17.06 Million USD | 228.87% |
| 2018 Q1 | 5.18 Million USD | -28.47% |
| 2018 FY | 22.25 Million USD | -14.26% |
| 2018 Q3 | - USD | -100.0% |
| 2017 Q4 | 7.25 Million USD | 0.0% |
| 2017 Q2 | 7.25 Million USD | 73.07% |
| 2017 Q1 | 4.19 Million USD | 0.0% |
| 2017 FY | 25.95 Million USD | 8839.06% |
| 2017 Q3 | 7.25 Million USD | -0.01% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | -297 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 921.529% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -454.0% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -151.361% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -678.09% |
| Better Therapeutics, Inc. | -2.72 Million USD | 49.249% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 427.646% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 93.957% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -35.586% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 80.471% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -434.749% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -2528.183% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 50.463% |
| Molecular Templates, Inc. | 50.39 Million USD | 102.748% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -1060.987% |
| NexImmune, Inc. | -1.02 Million USD | -35.126% |
| Orgenesis Inc. | -5.72 Million USD | 75.808% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 94.6% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -30002.152% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 104.713% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -183.629% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -496.983% |
| Trevena, Inc. | 1.45 Million USD | 195.189% |
| Vaxxinity, Inc. | -2.23 Million USD | 38.004% |
| Vaccinex, Inc. | -16 Million USD | 91.346% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -181.504% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 12029.371% |